Vaporized hydrogen peroxide uptake by tubing used for aseptic fill-finish manufacturing of biopharmaceutical drug products

dc.contributor.authorAli, Dilara
dc.contributor.authorPeláez, Sarah S.
dc.contributor.authorLemazurier, Thomas
dc.contributor.authorSchroeter, Ariane
dc.contributor.authorAdler, Michael
dc.contributor.authorBong, JaeHwi
dc.contributor.authorGermershaus, Oliver
dc.contributor.authorMahler, Hanns-Christian
dc.contributor.authorAllmendinger, Andrea
dc.date.accessioned2025-10-28T12:58:21Z
dc.date.issued2025
dc.description.abstractAseptic filling of biopharmaceutical products requires a grade A cleanroom environment, preferably ensured by isolators in grade C surroundings. Isolators are decontaminated before the start of filling processes using vaporized hydrogen peroxide (VHP) and filling starts at pre-defined residual VHP levels (e.g., below 0.5 ppm) depending on product sensitivity towards VHP oxidation. Manufacturing equipment and consumables, including filling assemblies, are exposed to VHP during or after the decontamination cycle or after line interruptions. We studied the VHP uptake by tubing in a lab-scale model isolator to evaluate the impact of tubing properties including contact material, tubing dimensions, suppliers, and VHP exposure (concentration and exposure time). Quantifying the release of H2O2 from the tubing into solution using an Amplex Red Hydrogen Peroxide Assay, showed that H2O2 concentrations decreased linearly with an increase in wall thickness and increased with higher surface to volume ratio. We further conclude that thermoplastic elastomer and thermoplastic vulcanizate tubing did not show any measurable VHP uptake for the tested conditions, whereas significant VHP uptake occurred in different platinum cured silicone tubing depending on tubing material and supplier. We further verified the results in a GMP manufacturing isolator setting. Based on our findings, we recommend to evaluate VHP uptake of filling tubing used for fill-finish manufacturing in isolators, to reduce the risk of oxidation for active pharmaceutical ingredients or excipients.
dc.identifier.doi10.1016/j.ejpb.2024.114618
dc.identifier.issn0939-6411
dc.identifier.issn1873-3441
dc.identifier.urihttps://irf.fhnw.ch/handle/11654/53399
dc.identifier.urihttps://doi.org/10.26041/fhnw-14052
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofEuropean Journal of Pharmaceutics and Biopharmaceutics
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectAseptic filling
dc.subjectDrug product filling
dc.subjectHydrogen peroxide
dc.subjectOxidation
dc.subjectSilicone tubing
dc.subjectSterilization
dc.subjectVaporized hydrogen peroxide
dc.subject.ddc600 - Technik, Medizin, angewandte Wissenschaften
dc.titleVaporized hydrogen peroxide uptake by tubing used for aseptic fill-finish manufacturing of biopharmaceutical drug products
dc.type01A - Beitrag in wissenschaftlicher Zeitschrift
dc.volume207
dspace.entity.typePublication
fhnw.InventedHereYes
fhnw.ReviewTypeAnonymous ex ante peer review of a complete publication
fhnw.affiliation.hochschuleHochschule für Life Sciences FHNWde_CH
fhnw.affiliation.institutInstitut für Pharmatechnologie und Biotechnologiede_CH
fhnw.openAccessCategoryHybrid
fhnw.pagination114618
fhnw.publicationStatePublished
relation.isAuthorOfPublication5f661671-2e22-4169-b24b-692dcfd2aed4
relation.isAuthorOfPublication.latestForDiscovery5f661671-2e22-4169-b24b-692dcfd2aed4
Dateien

Originalbündel

Gerade angezeigt 1 - 1 von 1
Lade...
Vorschaubild
Name:
1-s2.0-S0939641124004442-main.pdf
Größe:
3.33 MB
Format:
Adobe Portable Document Format

Lizenzbündel

Gerade angezeigt 1 - 1 von 1
Lade...
Vorschaubild
Name:
license.txt
Größe:
2.66 KB
Format:
Item-specific license agreed upon to submission
Beschreibung: